Abstract
Twenty patients (15 males), 5 to 20 years of age, with central diabetes insipidus (DI) were studied in order to evaluate efficacy, safety and adverse effects of oral desmopressin (DDAVP) treatment. Basal levels of plasma vasopressin were between 1.5 and 6.0 pg/ml. Evaluation was performed in two periods: during hospitalization (I) and ambulatory (A). Period I: Nineteen patients discontinued previous intranasal DDAVP treatment for a period equal or > to 24 hs. One patient had never been treated before. Water intake and diuresis, and plasma and urinary osmolality were measured before and during treatment. On the second day oral DDAVP was given, starting with 0.1 mg. Dose was gradually increased until a normal diuresis was attained. Period A: in 11 patients long-term (3 months) effect of treatment was evaluated. Results: Values are given in median and range. Table
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
